ACADIA Pharmaceuticals's yield on cost for the quarter that ended in Mar. 2026 was 0.00.
The historical rank and industry rank for ACADIA Pharmaceuticals's 5-Year Yield-on-Cost % or its related term are showing as below:
MEX:ACAD's 5-Year Yield-on-Cost % is not ranked *
in the Biotechnology industry.
Industry Median: 1.65 * Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
ACADIA Pharmaceuticals 5-Year Yield-on-Cost % Related Terms
MEX:ACAD vs VKTX, EWTX, DNLI: 5-Year Yield-on-Cost % Comparison
For the Biotechnology subindustry, ACADIA Pharmaceuticals's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ACADIA Pharmaceuticals 5-Year Yield-on-Cost % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ACADIA Pharmaceuticals's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where ACADIA Pharmaceuticals's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
ACADIA Pharmaceuticals (MEX:ACAD) has a 5-Year Yield-on-Cost % of 0.00 as of Jul. 11, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on ACADIA Pharmaceuticals and its competitors. According to the industry distribution chart, ACADIA Pharmaceuticals ranks #999999 out of 153 companies in the Biotechnology industry.
Is ACADIA Pharmaceuticals' 5-Year Yield-on-Cost % too high?
ACADIA Pharmaceuticals' current 5-Year Yield-on-Cost % is 0.00. Based on the distribution chart, ACADIA Pharmaceuticals ranks #999999 out of 153 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, ACADIA Pharmaceuticals has a GF Score™ of 74/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does ACADIA Pharmaceuticals' 5-Year Yield-on-Cost % compare to VKTX and EWTX?
According to the Biotechnology industry distribution chart, ACADIA Pharmaceuticals ranks #999999 out of 153 companies for 5-Year Yield-on-Cost %. This places ACADIA Pharmaceuticals in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 1.65. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Biotechnology company?
The median 5-Year Yield-on-Cost % among Biotechnology companies is 1.65, based on 153 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on ACADIA Pharmaceuticals and its competitors. For the Biotechnology industry, the median 5-Year Yield-on-Cost % is 1.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ACADIA Pharmaceuticals's current 5-Year Yield-on-Cost % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ACADIA Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, ACADIA Pharmaceuticals (MEX:ACAD) is currently considered Fairly Valued. The stock's GF Value™ is MXN496.85, compared to a current price of MXN460.00 — trading 7.4% below its estimated fair value. The current 5-Year Yield-on-Cost % is 0.00. ACADIA Pharmaceuticals' overall GF Score™ is 74/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For ACADIA Pharmaceuticals (MEX:ACAD), the current 5-Year Yield-on-Cost % is 0.00 as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ACADIA Pharmaceuticals (MEX:ACAD) Overvalued in 2026?
Based on GuruFocus' analysis, ACADIA Pharmaceuticals stock appears to be undervalued.
The current stock price of MXN460.00 is trading 7.4% below its estimated GF Value™ of MXN496.85.
GuruFocus considers ACADIA Pharmaceuticals to be Fairly Valued.
Key valuation signals for MEX:ACAD:
5-Year Yield-on-Cost %: 0.00
GF Value™: MXN496.85 vs. price of MXN460.00 (7.4% below fair value)
No single metric tells the full story. See the MEX:ACAD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-211, ACP-711, ACP-2591, etc.
74GF Score
Get the complete analysis for MEX:ACAD
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:ACAD has been successfully added to your 